Wyeth Is Poised To Drive Continued Operating Profit Growth Via Cost Containment Efforts Despite A Flat Prescription Pharma Growth Rate
Newly released report, Wyeth: PharmaVitae Profile, provides detailed company analysis
Published on November 10, 2009
by Press Office
(Companiesandmarkets.com and OfficialWire)
LONDON, ENGLAND
This analysis examines the historical and forecast performance for Wyeth in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Wyeth's performance against key rivals in the prescription pharmaceutical sector
*Assess the impact of Wyeth's impending acquisition by Pfizer
*Analyse how Wyeth is poised to drive continued operating profit growth via cost containment efforts despite a flat prescription pharma growth rate
The Affordable Business Wire of Choice For PR Professionals
OfficialWire was founded April 24, 2001 Follow Us @OfficialWire Journalist Registration Earn money with OfficialWire Join our Affiliate Program. Meet our Media Partners.
To advertise on OfficialWire simply register and upload your ad using our automated ad server.
This service is provided subject to OfficialWire's standard Terms and Conditions. Please read our Privacy Policy. OfficialWireฎ, Give Good PR , Be The News... & The Affordable Business Wire of Choice For PR Professionals are trademarks owned by Greg Smith OfficialWire, ISSN: 1550-1531, is continuously published by Greg Smith Compare OfficialWire to other press release distribution services Testimonials
—
